—
C+
C+ The full Closelooknet — membership. Open the C+ overview

LAKEFRONT BIOTHERAPEUTICS NV (LKFT.AS) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.
Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against LKFT.AS on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — LAKEFRONT BIOTHERAPEUTICS NV

LKFT.AS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Lakefront Biotherapeutics develops medicines for oncology and immunology in the United States and Europe. Its pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and lupus, and two CAR-T candidates, GLPG5101 and GLPG5301, made at the point of care and tested in phase 1/2 trials for lymphoma and myeloma. The company works with Gilead Sciences under a collaboration agreement and is based in Mechelen, Belgium, having taken its current name after operating as Galapagos.
Where it sits in the stack
Lakefront carries no seat in our index; it belongs to the healthcare sleeve of our universe, under the biotechnology industry, where the diary tracks clinical-stage drug and cell-therapy developers rather than build-out infrastructure.
Who it is priced against
Closelooknet's peer group for this name is not yet defined; the market compares it with other point-of-care CAR-T developers such as Legend Biotech, and it already has a working collaboration with Gilead Sciences.
Why Closelooknet tracks it
Lakefront holds no seat in our indices and has not yet built a Closelooknet score; it does not appear in any edition or quoted note in the diary.
What the diary watches
Whether the point-of-care manufacturing for its CAR-T candidates scales beyond early trials, and whether the collaboration with Gilead widens or narrows the pipeline it pursues alone.

LAKEFRONT BIOTHERAPEUTICS NV (LKFT.AS) trades on the AS exchange in Netherlands.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is LAKEFRONT BIOTHERAPEUTICS NV (LKFT.AS)?

LAKEFRONT BIOTHERAPEUTICS NV trades as LKFT.AS on the AS exchange (Netherlands) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is LKFT.AS in a Closelooknet index?

Not currently — LAKEFRONT BIOTHERAPEUTICS NV is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What does LAKEFRONT BIOTHERAPEUTICS NV do?

Lakefront Biotherapeutics develops medicines for oncology and immunology in the United States and Europe. Its pipeline includes GLPG3667, in a phase 2 trial for dermatomyositis and lupus, and two CAR-T candidates, GLPG5101 and GLPG5301, made at the point of care and tested in phase 1/2 trials for lymphoma and myeloma. The company works with Gilead Sciences under a collaboration agreement and is based in Mechelen, Belgium, having taken its current name after operating as Galapagos. Closelooknet's peer group for this name is not yet defined; the market compares it with other point-of-care CAR-T developers such as Legend Biotech, and it already has a working collaboration with Gilead Sciences.

Where does LAKEFRONT BIOTHERAPEUTICS NV sit in the AI build-out?

Lakefront carries no seat in our index; it belongs to the healthcare sleeve of our universe, under the biotechnology industry, where the diary tracks clinical-stage drug and cell-therapy developers rather than build-out infrastructure. Lakefront holds no seat in our indices and has not yet built a Closelooknet score; it does not appear in any edition or quoted note in the diary.

What does this page show?

A live price chart with SMA overlays and drawing tools for LKFT.AS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.